By Fineline Cube GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) announced that China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to GFH375, a KRAS G12D inhibitor, for treating KRAS G12D‑mutant metastatic pancreatic cancer patients who have received at least one prior systemic therapy. This marks the first BTD awarded for pancreatic cancer targeting this mutation in China.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Designation | Breakthrough Therapy Designation (BTD) |
| Product | GFH375 (KRAS G12D inhibitor) |
| Indication | KRAS G12D‑mutant metastatic pancreatic cancer (2L+) |
| Significance | First BTD for this indication in China |
| Global Synonym | VS‑7375 (Verastem Oncology) |
Drug Profile & Mechanism of Action
- Target: KRAS G12D – Most common KRAS mutation in pancreatic cancer (~40% of cases)
- Binding Mode: Non‑covalent inhibition of KRAS G12D protein
- Mechanism: Blocks interaction with downstream effector proteins, disrupting sustained pathway activation and suppressing tumor cell proliferation
- Preclinical Profile:
- Dose‑ and duration‑dependent tumor growth inhibition
- Low off‑target risk in kinase selectivity profiling
- Favorable safety target engagement
Global Clinical Development
| Region | Partner | Status | Regulatory Designation |
|---|---|---|---|
| China | GenFleet (originator) | BTD secured Apr 2026 | NMPA Breakthrough Therapy |
| United States | Verastem Oncology | Clinical initiated 2025 | FDA Fast‑Track |
GenFleet partnered with Verastem Oncology for overseas development; US trials commenced under FDA fast‑track status in 2025.
Market Context & Outlook
- Pancreatic Cancer Landscape: KRAS G12D mutations drive ~40% of cases; median survival for metastatic patients remains <12 months with existing chemotherapy, creating urgent demand for targeted therapies.
- First‑Mover Advantage: As the first KRAS G12D inhibitor to achieve BTD in China, GFH375 positions for accelerated NMPA review and priority assessment, potentially shaving 12–18 months off standard approval timelines.
- Global KRAS Market: Targeted KRAS inhibitors represent a US$5 billion+ addressable market; G12D subset previously considered “undruggable” until recent breakthroughs.
- Competitive Dynamics: Mirati/Amgen’s sotorasib (G12C) validated the class; G12D‑specific agents face less competition with larger eligible populations.
- Revenue Forecast: Peak China sales potential estimated at ¥2.5–4 billion (US$350‑550 million) assuming 2028‑2029 launch and 25‑30% penetration in 2L+ G12D‑mutant pancreatic cancer.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory pathways, clinical outcomes, and commercial projections for GFH375. Actual results may differ due to risks including trial failures, approval delays, competitive entry from other KRAS programs, and reimbursement negotiations.-Fineline Info & Tech